- Home
- UROY vs ZURA Comparison
UROY vs ZURA Comparison
Compare UROY & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UROY | ZURA |
|---|---|---|
| Founded | 2017 | 2022 |
| Country | Canada | United States |
| Employees | N/A | 30 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.8M | 521.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UROY | ZURA |
|---|---|---|
| Price | $3.73 | $5.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 2.1M | 620.3K |
| Earning Date | 03-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $279.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,584.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $0.99 |
| 52 Week High | $5.52 | $7.25 |
Technical Indicators
Market Signals| Indicator | UROY | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 50.70 | 40.13 |
| Support Level | $3.54 | $3.33 |
| Resistance Level | $4.07 | $5.75 |
| Average True Range (ATR) | 0.23 | 0.34 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 33.33 | 17.13 |
Price Performance
Historical ComparisonAbout UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.